Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure (BOND2)

An Open Label, Single Arm, Phase II, Multicenter Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients With Non-Muscle Invasive Bladder Carcinoma Who Have Failed BCG (Bacillus Calmette-Guerin) Therapy and Refused Cystectomy

To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.

Study Overview

• Status: Completed
• Conditions: Bladder Cancer
• Intervention / Treatment: Biological: CG0070

Detailed Description

The plan is to study the safety and efficacy of CG0070 in high-grade NMIBC (Non-muscle Invasive Bladder Cancer) patients who failed BCG therapy. Most patients with NMIBCis (Cis, Cis with Ta and/or T1, high grade Ta or T1 with frequent or uncontrolled recurrences) who have failed BCG (Bacillus Calmette-Guerin) intravesical therapy (standard of care) usually have no other choice but to proceed to cystectomy. Cystectomy is a surgery associated with major morbidity, mortality and quality of life issues. Morbidity and long term tedious medical care will be for the rest of the patient's life span. Most patients at this stage do not show signs of disease progression into the muscle layer or of metastasis, making surgery a very difficult decision. CG0070, if successful in this trial, will serve to provide a therapeutic alternative for this patient population in need.

• Study Type: Interventional
• Enrollment (Actual): 66
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alaska
    • Anchorage, Alaska, United States, 99503
      • Alaska Clinical Research Center
  • Arizona
    • Phoenix, Arizona, United States, 85032
      • BCG Oncology
    • Tucson, Arizona, United States, 85704
      • Arizona Institute of Urology
  • California
    • Los Angeles, California, United States, 90095
      • Institute of Urologic Oncology at UCLA
    • Orange, California, United States, 92868
      • UC Irvine Medical Center
    • San Diego, California, United States, 92093
      • University of California, San Diego
  • Florida
    • Gainesville, Florida, United States, 32610
      • UF Health Cancer Center
  • Illinois
    • Chicago, Illinois, United States, 60637
      • University of Chicago
  • Michigan
    • Troy, Michigan, United States, 48084
      • Michigan Institute of Urology, P.C.
  • Nebraska
    • Omaha, Nebraska, United States, 68114
      • Adult Pediatric Urology and Urogynecology, PC
    • Omaha, Nebraska, United States, 68130
      • GU Research Network/ The Urology Center
  • New Jersey
    • Edison, New Jersey, United States, 08837
      • Premier Urology Group, LLC.
  • New York
    • Poughkeepsie, New York, United States, 12061
      • Premier Medical Group of the Hudson Valley
  • North Carolina
    • Winston-Salem, North Carolina, United States, 27157
      • Wake Forest University School of Medicine
  • Ohio
    • Cincinnati, Ohio, United States, 45212
      • The Urology Group
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Vanderbilt University Medical Center, Dept. of Urologic Surgery
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Medical College of Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients must have pathologically confirmed non-muscle invasive bladder cancer (NMIBC) high grade disease (HG), as defined by the 2004 WHO classification system
2. Patients must have no evidence of muscle invasive disease
3. Patients must be able to provide a sufficient biopsy sample to the central pathologist for histopathologically confirmed, transitional cell (urothelial) carcinoma. Urothelial tumors with mixed histology (but with <50% variant) are eligible.
4. Patients must have received at least two or more prior courses of intravesical therapy per recommended schedules. Bacillus Calmette-Guerin (BCG) must have been one of the prior therapies administered.
5. Patients can have either failed BCG induction therapy within a six-month period or have been successfully treated with BCG, but subsequently found to have recurrence. The first standard course of intravesical BCG therapy must include at least six weekly treatments (allowable range of instillations per course is 4-9). The second course of BCG therapy must include at least two weekly treatments.

6. Patients have either Cis or Cis with Ta and/or T1 disease at enrollment or in the past. For those patients with only Ta or T1 disease at enrollment AND with no history of Cis, they must have

   • disease recurrence either must occur within 12 months of the most recent intravesical therapy of any kind, OR
   • disease recurrence within 18 months of BCG maintenance OR
   • disease recurrence within 24 months of BCG induction
   • T1 patients need to have evidence of muscle included in their latest biopsy; and if not a re-TURBT has to be done prior to enrollment
7. 18 years of age or older
8. Radical cystectomy has been declined by the patient in a signed special section of the informed consent, whereby there is a clear explanation by the investigator to the subject that a delay of cystectomy may increase his/her chance of disease progression, the results of which may lead to serious and life threatening consequences.
9. Patients must be able to enter into the study within ten weeks of their most recent diagnostic procedure, which is usually a diagnostic biopsy, a transurethral resection of bladder tumor (TURBT) procedure or positive urine cytology.
10. Eastern Cooperative Oncology Group (ECOG) performance status <2.
11. Not pregnant or lactating
12. Patients with child bearing potential must agree to use adequate contraception
13. Agree to study specific informed consent and HIPAA authorization for release of personal health information

14. Adequate baseline CBC, renal and hepatic function. Parameters described as WBC>3000 cells/mm^3, ANC>1,000 cells/mm^3, hemoglobin>9.5g/dL, and platelet count >100,000 cells/mm^3

    • Adequate renal function: serum creatinine <2.5mg/dL
    • Bilirubin, AST and ALT not more than 2 x Upper Limits of Normal
    • PT/INR, PTT, and fibrinogen within institutional acceptable limits
    • Absolute lymphocyte count ≥ 800/μL before the first dose of CG0070

Exclusion Criteria:

1. Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior immunotherapy or intravesical (administered within the bladder) chemotherapy for superficial disease is acceptable
2. History of anaphylactic reaction following exposure to humanized or human therapeutic monoclonal antibodies, hypersensitivity to GM-CSF or yeast derived products, clinically meaningful allergic reactions or any known hypersensitivity or prior reaction to any of the formulation excipients in the study drugs.
3. Known infection with HIV, HBV or HCV.
4. Anticipated use of chemotherapy or radiotherapy not specified in the study protocol while on study
5. Any underlying medical condition that, in the Investigator's opinion, will make the administration of study vector hazardous to the patient, would obscure the interpretation of adverse events, or not permit adequate surgical resection.
6. Systemic treatment on any investigational clinical trial within 28 days prior to registration.
7. Concurrent treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (exception: inhaled or topically applied steroids, and acute and chronic standard dose NSAIDs, are permitted). Use of a short course (i.e., ≤ 1 day) of a glucocorticoid is acceptable to prevent a reaction to the IV contrast used for CT scans.
8. Immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry.
9. History of prior experimental cancer vaccine treatment (e.g., dendritic cell therapy, heat shock vaccine) within the last year
10. History of stage III or greater cancer, excluding urothelial cancer. Basal or squamous cell skin cancers must have been adequately treated and the subject must be disease-free at the time of registration. Subjects with a history of stage I or II cancer, must have been adequately treated and have been disease-free for ≥ 2 years at the time of registration.

11. Progressive or persistent viral or bacterial infection

    • All infections must be resolved and the patient must remain afebrile for seven days without antibiotics prior to being placed on study
    • Urinary tract infection, including particularly bladder infection, must be resolved prior to being placed on study
12. Unwilling or unable to comply with the protocol or cooperate fully with the investigator and site personnel

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CG0070; Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.	Biological: CG0070; Other Names: oncolytic adenovirus with a E2F promotor and expresses GMCSF

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Durable Complete Response Proportion (DCR)	Defined as the proportion of patients who experience a durable complete response lasting 12 months or longer from the initial confirmed complete response date (first CR assessment to be at least 6 months after the first intravesical intervention) and at least 18 months from the date of the first intravesical intervention	18 months time point from the date of the first intravesical intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cystectomy Free Survival	Not available, not collected on study or not currently available	18 months after the first intravesical treatment
Complete Response Survival	Not available, not collected on study or not currently available	18 months after the first intravesical treatment
Progression Free Survival	Not available, not collected on study or not currently available	18 months after the first intravesical treatment
Time to Progression to Muscle Invasive Disease	Not available, not collected on study or not currently available	18 months after the first intravesical treatment
Overall Survival	Not available, not collected on study or not currently available	18 months and 24 months after first intravesical treatment
PD-L1 Status Changes	PD-L1 status of cancer cells and immune cells at tumor site by IHC	changes between pre-intervention and post intervention at either cystectomy or at biopsy up to 24 months
Organ Confined Disease Proportions	Patient proportions with no cancer cells in regional lymph nodes at cystectomy	at cystectomy
Complete Response Proportions	Proportions of patients with a complete response of at least 12 months' duration	24 months after the first intravesical treatment
PD-1 Status Changes	PD-1 status of immune cells at tumor site by IHC	changes between pre-intervention and post intervention at either cystectomy or at biopsy up to 24 months
Disease Regression Proportions	Proportions of patients with a partial response and/or a complete response of less than 12 months' duration	24 months after the first intravesical treatment

Collaborators and Investigators

• Sponsor: CG Oncology, Inc.
• Investigators: Principal Investigator: Gary Steinberg, MD, University of Chicago

Study record dates

Study Major Dates

• Study Start (Actual): June 2, 2015
• Primary Completion (Actual): August 1, 2018
• Study Completion (Actual): February 1, 2019

Study Registration Dates

• First Submitted: February 9, 2015
• First Submitted That Met QC Criteria: February 11, 2015
• First Posted (Estimate): February 19, 2015

Study Record Updates

• Last Update Posted (Actual): April 14, 2021
• Last Update Submitted That Met QC Criteria: April 12, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Keywords: Bladder Cancer
• Additional Relevant MeSH Terms: Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Urologic Diseases; Urinary Bladder Diseases; Urinary Bladder Neoplasms
• Other Study ID Numbers: BOND 2 version 3.8

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No